Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Trevena, Inc. (TRVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4181-0.0419 (-9.11%)
At close: 04:00PM EDT
0.4360 +0.02 (+4.28%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.4600
Open0.4528
Bid0.4380 x 1300
Ask0.4400 x 4000
Day's Range0.3725 - 0.4800
52 Week Range0.1810 - 1.8600
Volume22,389,731
Avg. Volume2,271,448
Market Cap69.204M
Beta (5Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-0.3530
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TRVN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Trevena, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/29/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care

    CHESTERBROOK, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication in Expert Review of Neurotherapeutics titled “A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain” by Eugene R. Viscusi, M.D., Director of Acute Pain Management at Jefferson He

  • GlobeNewswire

    Trevena to Participate at the JMP Securities Life Sciences Conference

    CHESTERBROOK, Pa., June 10, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO, and Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held in New York on June 15 - 16, 2022. Fires

  • GlobeNewswire

    Trevena to Present at the H.C. Wainwright Global Investment Conference

    CHESTERBROOK, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO and Barry Shin, CFO, will be participating in the H.C. Wainwright Global Investment Conference being held May 23 - 26, 2022. H.C. Wainwright Global Investment Conference (Hybrid Conference) Date: Tuesday, May 24

Advertisement
Advertisement